Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD).
For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

Tonix Pharmaceuticals is also enrolling participants in a Phase 3 trial for fibromyalgia.
For more information, please visit www.thereliefstudy.com or www.clinicaltrials.gov (NCT04172831).

News & Events

: Press Releases

Home
News & Events
Press Releases

Press Releases

Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology

May 23, 2018 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

May 14, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention

May 7, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease

May 1, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

April 4, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

April 3, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL

March 21, 2018 • 4:05 PM EDT

Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

March 13, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update

March 12, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference

March 6, 2018 • 7:00 AM EST

News & Events : Press Releases